Matthew Ren Silver
Cell Signaling Technology
13 Papers
62 Citations
Matthew Ren Silver is an academic researcher from Cell Signaling Technology. The author has contributed to research in topics: Kinase activity & Anaplastic lymphoma kinase. The author has an hindex of 7, co-authored 13 publications.
Chat about Author
Papers
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly,Jason R. Brown,Kurt A. Schalper,Herbert Haack,Matthew Ren Silver,Christian Nixon,Veerle Bossuyt,Lajos Pusztai,Donald R. Lannin,David L. Rimm +9 more
TL;DR: PD-L1 expression was observed in 30% of patients, and it was positively associated with hormone-receptor–negative and triple-negative status and high levels of TILs, indicating a subset of patients that may benefit from immune therapy.
367
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Victoria Rimkunas,Katherine Crosby,Daiqiang Li,Yerong Hu,Meghan E. Kelly,Ting-Lei Gu,Jennifer S. Mack,Matthew Ren Silver,Xinmin Zhou,Herbert Haack +9 more
TL;DR: The ROS1 IHC assay described here is a valuable tool for identifying patients expressing mutant ROS1 and could be routinely applied in clinical practice to detect lung cancers that may be responsive to targeted therapies.
308
IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation
Matthew Ren Silver,Alexander Margulis,Wood Nancy L,Samuel J. Goldman,Marion T. Kasaian,Divya Chaudhary +5 more
TL;DR: IL-33 amplifies inflammation in both IgE-independent and Ig E-dependent responses in both primary mast cells and basophils.
138
Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).
Joseph McLaughlin,Kurt A. Schalper,Daniel E. Carvajal-Hausdorf,Vamsidhar Velcheti,Herbert Haack,Matthew Ren Silver,Sarah B. Goldberg,Roy S. Herbst,David L. Rimm +8 more
TL;DR: The PD-L1 protein expression test is being explored as a companion predictive test for anti-PD-1 therapies but studies from this group reveal limitations of available antibodies and antibodies against PD-1.
20
Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.
Victoria Rimkunas,K. Crosby,M. Kelly,Matthew Ren Silver,K. Hincman,R. Polakiewicz,D.Q. Li,X.M. Zhou,Herbert Haack +8 more
TL;DR: An IHC-based assay is developed for the detection of low level ALK and ROS in NSCLC patients with high specificity and sensitivity and is reasoned that an immunohistochemistry (IHC)-based assay could provide a fast, inexpensive alternative for diagnosing patients with ALK
13